Key result
Hyperglycemic-albuminuric stage 2 CKM linked to ~2.6-fold higher all-cause mortality vs stages 0/1.
Why the study?
Stage 2 CKM syndrome represents an important window for primary prevention, but it encompasses heterogeneous cardiometabolic risk profiles whose distinct phenotypes, temporal trends, sociodemographic distribution, and mortality risks were uncharacterized.
Do distinct data-driven phenotypes of stage 2 cardiovascular-kidney-metabolic (CKM) syndrome differ in their temporal trends, sociodemographic distribution, and risks of all-cause and cardiovascular mortality among U.S. adults?
Cohort (n=8,761)
Do distinct data-driven phenotypes of stage 2 cardiovascular-kidney-metabolic (CKM) syndrome differ in their temporal trends, sociodemographic distribution, and risks of all-cause and cardiovascular mortality among U.S. adults?
Stage 2 CKM syndrome comprises four distinct phenotypes with diverging temporal trends and mortality risks, with the rising hyperglycemic-albuminuric phenotype carrying more than a 4-fold increased risk of cardiovascular mortality.
Answers are grounded in this paper and cite their sources.
May inform phenotype-based risk stratification in stage 2 CKM; leaves open whether targeted interventions improve outcomes.
BACKGROUND: Stage 2 cardiovascular-kidney-metabolic (CKM) syndrome is common and represents an important window for primary prevention, but it encompasses heterogeneous cardiometabolic risk profiles. OBJECTIVES: We aim to identify the distinct phenotypes of stage 2 CKM among U.S. adults and characterize their temporal trends, sociodemographic distribution, and mortality risks. METHODS: We analyzed 8,761 adults aged ≥20 years with stage 2 CKM from the National Health and Nutrition Examination Survey, 1999 to 2018, with mortality follow-up through 2019. Latent profile analysis incorporated 9 age-residualized, standardized biomarkers across adiposity, blood pressure, glycemic, lipid, and kidney domains. We assessed the prevalence, trends, and sociodemographic distribution of the distinct stage 2 CKM phenotypes. Survey-weighted Cox models estimated mortality associations using CKM stages 0/1 as the reference. RESULTS: Four phenotypes were identified: lean-hypertensive (23.3%), overweight-dyslipidemic (40.7%), obesity-metabolic (26.2%), and hyperglycemic-albuminuric (9.8%). From 1999-2000 to 2017-2018, hyperglycemic-albuminuric increased from 6.0% to 12.1% and obesity-metabolic from 22.3% to 30.6%, whereas lean-hypertensive declined from 31.0% to 20.8% (all P for trend<0.001). Hyperglycemic-albuminuric was disproportionately prevalent among non-Hispanic Black adults and those with lower income or educational attainment. During a median 10-year follow-up, 484 deaths occurred, including 117 cardiovascular disease deaths. Hyperglycemic-albuminuric was associated with the highest risks of all-cause (HR: 2.59; 95% CI: 1.95-3.45) and cardiovascular disease mortality (HR: 4.49; 95% CI: 2.47-8.15). CONCLUSIONS: Stage 2 CKM comprises distinct phenotypes with differing cardiometabolic risk profiles, temporal trends, sociodemographic patterns, and mortality risk among U.S. adults. These findings underscore the need for targeted and equitable CKM prevention and management strategies.
No takes yet. Share an insight, caveat, or question.
Yao et al. (2026) conducted a cohort in Stage 2 cardiovascular-kidney-metabolic (CKM) syndrome (n=8,761). Distinct stage 2 CKM phenotypes (lean-hypertensive, overweight-dyslipidemic, obesity-metabolic, hyperglycemic-albuminuric) vs. CKM stages 0/1 (reference for mortality analyses) was evaluated on All-cause mortality (HR 2.59, 95% CI 1.95-3.45). The hyperglycemic-albuminuric stage 2 CKM phenotype was associated with the highest risks of all-cause and CVD mortality vs CKM stages 0/1.
Synapse has enriched 10 related papers. Consider them for comparative context: